People: Affymetrix Inc (AFFX.O)
AFFX.O on Nasdaq
3.69USD
17 May 2013
3.69USD
17 May 2013
Price Change (% chg)
$-0.02 (-0.54%)
$-0.02 (-0.54%)
Prev Close
$3.71
$3.71
Open
$3.73
$3.73
Day's High
$3.78
$3.78
Day's Low
$3.66
$3.66
Volume
349,579
349,579
Avg. Vol
671,242
671,242
52-wk High
$5.50
$5.50
52-wk Low
$2.96
$2.96
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Stephen Fodor |
59 | 2009 | Executive Chairman of the Board |
Frank Witney |
59 | 2011 | President, Chief Executive Officer, Director |
Timothy Barabe |
59 | 2010 | Chief Financial Officer, Executive Vice President |
Andrew Last |
53 | 2012 | Executive Vice President - Genetic Analysis Business Unit |
David Weber |
59 | 2013 | Executive Vice President - Global Commercial Operations |
Siang Chin |
2013 | General Counsel, Secretary | |
Robert Wayman |
67 | 2010 | Lead Independent Director |
Nelson Chan |
51 | 2010 | Independent Director |
Gary Guthart |
47 | 2009 | Independent Director |
Jami Nachtsheim |
54 | 2010 | Independent Director |
Robert Trice |
66 | 2006 | Independent Director |
Doug Farrell |
Vice President - Investor Relations & Treasury |
Biographies
| Name | Description |
|---|---|
Stephen Fodor |
Dr. Stephen P. A. Fodor, Ph.D., is Executive Chairman of the Board of Affymetrix Inc. Dr. Fodor has served as director since 1993. He served as Chief Executive Officer from 1997 to 2008 and as Chairman from 1999 to present. At various times between 1993 and 1997, Dr. Fodor served as President, Chief Operating Officer and Chief Technology Officer. Dr. Fodor was Vice President and Director of Physical Sciences at the Affymax Research Institute from 1989 to 1993. Dr. Fodor is the founder and Chief Executive Officer of Cellular Research, Inc. and serves as a Trustee of the Carnegie Institution of Science and as a member of the National Academy of Engineering. Dr. Fodor also serves on a variety of scientific advisory boards. The Board of Directors selected Dr. Fodor as a director nominee because he is the founder of the Company and former Chief Executive Officer. |
Frank Witney |
Dr. Frank Witney, Ph.D., is President, Chief Executive Officer, Director of Affymetrix, Inc. Dr. Witney has served as President, Chief Executive Officer and a director since July 2011. Dr. Witney served as President and Chief Executive Officer of Dionex Corporation from April 2009 to May 2011. Between December 2008 and April 2009, Dr. Witney served as Executive Vice President and Chief Commercial Officer. Previously, Dr. Witney served as President and Chief Executive Officer of Panomics, Inc. from July 2002 to December 2008. |
Timothy Barabe |
Mr. Timothy C. Barabe is Chief Financial Officer and Executive Vice President of Affymetrix Inc. Mr. Barabe previously worked at Human Genome Sciences, Inc., where he served as Senior Vice President and Chief Financial Officer from July 2006 until March 2010. From September 2004 to June 2006, Mr. Barabe was at Molnlycke Health Care, a privately owned surgical supply company, most recently as its U.K. Managing Director. Mr. Barabe was with Novartis AG from 1982 to 2004 in several senior executive positions. Mr. Barabe is a member of the Board of Directors of ArQule, Inc. Mr. Barabe will retire from Affymetrix in 2013. |
Andrew Last |
Dr. Andrew J. Last, Ph.D., is Executive Vice President - Genetic Analysis Business Unit of Affymetrix Inc. He joined the company in December 2009 and currently serves as Executive Vice President, Genetic Analysis Business Unit. Prior to joining Affymetrix, Dr. Last served on the leadership team of BD Biosciences Cell Analysis Unit, a segment of Becton Dickinson and Company, from 2004 to 2009, where he was Vice President, Global Marketing & Strategic Planning and General Manager of the San Diego-based Pharmingen business. Before joining Becton Dickinson, Dr. Last was a member of Applera Corporation’s Applied Biosystems unit leadership team from 2002 to 2004 as Vice President & General Manager of the Gene Expression business. |
David Weber |
Mr. David Weber is Executive Vice President - Global Commercial Operations of Affymetrix Inc. Between December 2011 and February 2013, he served as Senior Vice President, Global Commercial Operations. From June 2010 to December 2011, Mr. Weber was a consultant to various biotechnology companies. Mr. Weber was at Cyntellect Inc. as its Vice President, Sales from July 2009 to June 2010. Mr. Weber was with The Linus Group from February 2008 to June 2009 as its Vice President of the Life Sciences Practice. Previously, Mr. Weber served as President and CEO of Eksigent Technologies, Senior Vice President of Marketing and Business Development of Stratagene Corp., and President, Americas Region, for Amersham Biosciences (GE Healthcare). |
Siang Chin |
Ms. Siang Chin has been appointed as General Counsel, Secretary of Affymetrix Inc., effective March 31, 2013. Ms. Chin has practiced law for over 15 years. Prior to joining the Company, she was associated with the law firms of Shearman & Sterling and Slaughter and May. |
Robert Wayman |
Mr. Robert P. Wayman serves as Lead Independent Director of Affymetrix Inc. Mr. Wayman is a member of the Audit Committee and the Nominating and Corporate Governance Committee. Mr. Wayman served as Executive Vice President and Chief Financial Officer of Hewlett-Packard Company from 1984 until his retirement in December 2006. Mr. Wayman also served as Interim Chief Executive Officer of Hewlett-Packard Company from February 2005 through March 2005 and served on the Board of Directors of Hewlett-Packard Company from February 2005 to March 2007 and from 1993 to 2002. Mr. Wayman has served as a director of CareFusion Corp. since 2009. |
Nelson Chan |
Mr. Nelson C. Chan is an Independent Director of Affymetrix Inc. Mr. Chan has served as a director since March 2010 and is the Chairman of the Audit Committee and a member of the Compensation Committee. Mr. Chan served as Chief Executive Officer of Magellan Navigation, Inc. from 2006 to 2008. From 1992 through 2006, Mr. Chan served in various senior management positions with SanDisk Corporation, including most recently as Executive Vice President and General Manager, Consumer Business. Mr. Chan is a member of the Board of Directors of Coinstar, Inc. and Synaptics Incorporated. |
Gary Guthart |
Dr. Gary S. Guthart Ph.D., is Independent Director of Affymetrix Inc. Dr. Guthart has served as a director since May 2009 and is a member of the Compensation Committee. Dr. Guthart has served as the Chief Executive Officer of Intuitive Surgical, Inc. since January 2010. Dr. Guthart joined Intuitive Surgical, Inc. in April 1996, became Chief Operating Officer in 2006, and was promoted to President in 2007. Prior to joining Intuitive Surgical, Inc., Dr. Guthart was part of the core team developing foundation technology for computer enhanced-surgery at SRI International (formally Stanford Research Institute). Dr. Guthart serves on the Board of Directors of Intuitive Surgical, Inc. |
Jami Nachtsheim |
Ms. Jami Dover Nachtsheim serves as Independent Director of Affymetrix Inc. Ms. Nachtsheim has served as a director since March 2010 and is the Chairwoman of the Compensation Committee. Ms. Nachtsheim served in a variety of positions with Intel Corporation from 1980 until her retirement in 2000, most recently as Corporate Vice President of the Sales and Marketing Group and Director of Worldwide Marketing. Ms. Nachtsheim is a member of the Board of Directors of FEI Company and The Tech Museum of Innovation. |
Robert Trice |
Dr. Robert H. Trice, Ph.D., serves as an Independent Director of Affymetrix Inc. Dr. Trice has served as a director since 2006, is the Chairman of the Nominating and Corporate Governance Committee and a member of the Audit Committee. Dr. Trice served as Senior Vice President for Business Development at Lockheed Martin Corporation from October 1998, and assumed additional duties as Senior Vice President for Strategy and Business Development at Lockheed Martin Corporation from March 2009 until his retirement in January 2011. |
Doug Farrell |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Stephen Fodor |
188,970 |
Frank Witney |
657,291 |
Timothy Barabe |
436,137 |
Andrew Last |
425,403 |
David Weber |
-- |
Siang Chin |
-- |
Robert Wayman |
-- |
Nelson Chan |
-- |
Gary Guthart |
-- |
Jami Nachtsheim |
-- |
Robert Trice |
-- |
Doug Farrell |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Stephen Fodor |
923,603 | 13,672,174 |
Frank Witney |
0 | 0 |
Timothy Barabe |
0 | 0 |
Andrew Last |
0 | 0 |
David Weber |
0 | 0 |
Siang Chin |
0 | 0 |
Robert Wayman |
0 | 0 |
Nelson Chan |
0 | 0 |
Gary Guthart |
0 | 0 |
Jami Nachtsheim |
0 | 0 |
Robert Trice |
0 | 0 |
Doug Farrell |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
BARABE TIMOTHY C |
2,182 | $4.68 |
LAST ANDREW J |
1,097 | $3.85 |
RUNKEL JOHN F JR |
615 | $3.85 |
BARABE TIMOTHY C |
1,097 | $3.85 |
LAST ANDREW J |
30,000 | $0.00 |
WITNEY FRANKLIN R |
60,000 | $0.00 |
WITNEY FRANKLIN R |
25,000 | $0.00 |
WITNEY FRANKLIN R |
22,009 | $3.17 |
LAST ANDREW J |
1,835 | $3.32 |
RUNKEL JOHN F JR |
4,127 | $3.01 |
BARABE TIMOTHY C |
4,127 | $3.01 |
RUNKEL JOHN F JR |
2,751 | $3.55 |
BARABE TIMOTHY C |
10,000 | $3.75 |
RUNKEL JOHN F JR |
734 | $3.88 |
FODOR STEPHEN P A |
1,834 | $3.88 |
LAST ANDREW J |
1,376 | $3.86 |
RUNKEL JOHN F JR |
918 | $3.86 |
BARABE TIMOTHY C |
1,376 | $3.86 |
FODOR STEPHEN P A |
1,193 | $3.86 |
BARABE TIMOTHY C |
5,550 | $3.99 |
BARABE TIMOTHY C |
4,450 | $3.99 |
LAST ANDREW J |
10,000 | $4.06 |
WITNEY FRANKLIN R |
13,755 | $4.39 |
FODOR STEPHEN P A |
2,293 | $4.69 |
TRICE ROBERT H JR |
11,500 | $0.00 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
